Newsroom

Industry News

20 Mar

Nemus Bioscience Signs Development Agreement with Nanomerics to Advance Ocular Formulation of NB1111 for the Treatment of Glaucoma Using Proprietary Molecular Envelope Technology (MET)

COSTA MESA, CA–(Marketwired – Mar 20, 2017) – NEMUS Bioscience, Inc. ( OTCQB : NMUS ) announced that the company has signed a development agreement with Nanomerics Ltd. of the United Kingdom, to develop a topical ocular formulation of tetrahydrocannabinol-valine-hemisuccinate (THCVHS), the prodrug of THC, which is the active...

Read more

17 Mar

Actinium Pharmaceuticals to Sponsor 4th Annual Summit on Hematologic Malignancies

NEW YORK, March 16, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc.  (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that the Company is a sponsor of Oncology Meeting Innovations’ 4thAnnual Summit on Hematologic Malignancies, which is...

Read more

17 Mar

Cytori to Webcast Fourth Quarter Financial Results on March 23rd

SAN DIEGO, March 17, 2017 (GLOBE NEWSWIRE) — Cytori Therapeutics, Inc. (CYTX) will provide a live webcast of its fourth quarter financial results and business update on Thursday, March 23, 2017 at 5:30 PM Eastern Time. The dial-in information is as follows: Dial-In Number: +1.877.402.3914 Conference ID: 90778155 Prior...

Read more

17 Mar

Nephros Announces $1.2 Million Private Placement

RIVER EDGE, NJ–(Marketwired – Mar 17, 2017) – Nephros, Inc. ( OTCQB : NEPH ) (the “Company”), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis (HD) machine for the treatment of...

Read more

16 Mar

BioLineRx to Report Annual 2016 Results on March 23, 2017

TEL AVIV, Israel, March 16, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will release its audited annual financial results for the year ended December 31, 2016 on Thursday, March 23, 2017, before the US markets open. The Company will...

Read more

16 Mar

Intellipharmaceutics Announces TSX Trading Symbol Change to “IPCI”

TORONTO, March 16, 2017 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (IPCI) (TSX:I)  (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs announced that, effective at the opening of trading on Monday, March 20,...

Read more

Page 2 of 22212345...102030...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address